- Pharmacist Job Market in 2020: Hospital Employment Up, Retail Salaries Down (drugchannels.net)
The Bureau of Labor Statistics has recently released its employment and salary data for 2020. That means it’s time to update Drug Channels Institute’s annual analysis of pharmacist salaries and employment...We have found that the share of pharmacists who work at hospitals reached a new high. What’s more, average base salaries for retail pharmacists have dropped, while salaries have risen for pharmacists employed by hospitals, physician offices, and other non-retail settings...READ MORE
- Bristol-Myers is sued for $6.4 billion over delayed cancer drug (reuters.com)
Bristol Myers Squibb Co was sued for $6.4 billion...allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which the drugmaker bought in 2019...According to a complaint in Manhattan federal court, Bristol Myers failed to use contractually required "diligent efforts" to win U.S. Food and Drug Administration approval for the non-Hodgkin lymphoma drug by a Dec. 31, 2020, deadline...By missing the deadline, Bristol Myers was excused from owing an additional $9 in cash to Celgene shareholders for each share they held, enabling it to acquire Celgene at an "enormous discount" and enjoy a "windfall," the complaint said...READ MORE
- ICER, vocal critic of drug company pricing, turns scrutiny to insurers (biopharmadive.com)
The Institute for Clinical and Economic Review, a nonprofit and frequent critic of drugmakers for excessively high drug prices, now plans to assess how health insurance policies harm patient access to care...This follows research by the group that argued cost-sharing should not be structured to shift healthcare costs to patients when they have no medically appropriate lower-cost option...ICER's review will not, however, look at whether cost-sharing should be reduced for drugs on which payers receive large rebates or whether payers should be asked to demonstrate how their policies on drug access save overall healthcare costs...READ MORE
- Eli Lilly hit with DOJ subpoena over New Jersey factory making COVID-19 drug (fiercepharma.com)
...Eli Lilly’s COVID-19 drug factory in New Jersey garnered unwanted headlines for quality control snafus and alleged document tampering. Now, the Department of Justice has stepped in to investigate...Lilly revealed the DOJ has issued a subpoena demanding documents relating to the site in Branchburg, New Jersey. The site produces doses of Lilly's COVID-19 antibody treatment, which has recently faced setbacks for its susceptibility to certain variants...In early May, Reuters reported that employees at the site accused an executive of altering FDA-required documents in an effort to downplay serious quality control problems...READ MORE
- Wisconsin pharmacist sentenced to 3 years in prison for tampering with COVID-19 vaccine doses (cbsnews.com)
A former pharmacist in Wisconsin who intentionally tampered with more than 500 doses of a COVID-19 vaccine was sentenced to three years in prison on Tuesday. Steven Brandenburg, 46, pleaded guilty in February to two felony counts of attempting to tamper with a consumer product...He had admitted to intentionally removing the doses manufactured by Moderna from a refrigerator for hours at Aurora Medical Center in Grafton, located just north of Milwaukee...READ MORE
- COVID-19 Update: New Naming System, Support for Investigation and More (biospace.com)
News continues to come out about COVID-19, including support for an investigation into the origins of the virus, a new naming system, and legal discussions of whether employers can mandate vaccination. Here’s a look...READ MORE
- WHO Creates Naming System for COVID-19 Variants
- Scientists Support Full Investigation of Viral Leak Theory
- US Companies Can Legally Mandate Vaccinations
- New Variant from Vietnam is Highly Contagious
- Moderna Initiates Rolling Submission to FDA for Full Approval of COVID-19 Vaccine
- Pandemic relief: Pharma sales rep salaries—and job satisfaction—actually increased in 2020 (fiercepharma.com)
It turns out pharma sales reps didn't need to worry about a pandemic effect on their salaries. Pharma reps’ average pay jumped to $158,013 in 2020 from $151,217 the previous year, according to MedReps’ annual survey...That’s good news for the three-fourths of reps who last March said they were concerned about pay cuts. What actually happened? Only 14% reported earning less money during 2020...READ MORE
- After breakout year, Moderna on track to generate $15B+ in 2022 thanks to more demand, higher prices: analysts (fiercepharma.com)
Moderna is hard at work ramping up production of its mRNA COVID-19 vaccine, which is projected to reap over $19 billion for the company by year’s end. But given that the pandemic is easing in parts of the world, what’s less certain is how 2022 will play out…After a breakout year, Moderna sees strong reason to believe 2021 won't be a one-off boom year. That's thanks to the predicted need for booster shots and additional supply deals coupled with stronger pricing power…READ MORE
- U.S. Supreme Court rebuffs J&J appeal over $2 billion baby powder judgment (reuters.com)
The U.S. Supreme Court...declined to hear Johnson & Johnson’s bid to overturn a $2.12 billion damages award to women who blamed their ovarian cancer on asbestos in the company’s baby powder and other talc products ...The justices turned away a J&J appeal and left in place a Missouri state court ruling in litigation brought by 22 women whose claims were heard together in one trial...READ MORE
- Bayer hits major Roundup setback—again—as judge rejects ‘unreasonable’ $2B settlement (fiercepharma.com)
Bayer’s efforts to put an end to the consuming Roundup litigation have hit a wall, raising uncertainties over the weedkiller’s future and its impact on the German conglomerate’s financial position...A U.S. federal judge in San Francisco...rejected Bayer’s already revised $2 billion proposal to settle potential future lawsuits alleging Roundup causes cancer. The deal would have put a halt to litigation over four years, during which time eligible plaintiffs could have received compensation of up to $200,000 each...READ MORE